RANDOMIZED TRIAL OF BREAST SELF EXAMINATION IN SHANGHAI

描述：（改编自申请人摘要）。 本申请 要求继续支持最后五年的随机试验， 目前正在上海纺织435家工厂进行疯牛病检查 工业局。 研究的目的是确定 定期进行疯牛病治疗将降低乳腺癌的死亡率。 超过 267 000名30至64岁的在职和退休女工， 1989人按工厂随机分为干预组或对照组。 妇女 在1989-91年接受BSE初始指导的干预组中， 一九九一至九二年度及一九九三至九五年度的加强训练课程，以及多个临时训练课程， 提醒他们练习BSE，并由医务人员监督他们的BSE 一年两次。 对所有妇女的生命状况进行积极跟踪， 居住在上海，并采用多种主动和被动方法 来识别所有偶发和致命的乳腺癌。 高水平的 遵守和能力，在实践疯牛病的前五年， 审判记录，因为有能力跟踪高比例的 并确定几乎所有的乳腺癌死亡。 作为 根据乳房X光检查试验的结果， 两个研究组到第4年随访（1994年）的比率相似， 和后续行动10年（至2000年）， 预计，将是必要的，并在此更新申请中提出。 未提议进一步的干预活动。 经过10年的 随访中，将累积超过260万女性年， 将有80%的能力检测出乳腺癌死亡率降低30%。

DESCRIPTION: (Adapted from Applicant's Abstract). This application requests continued support for the final five years of a randomized trial of BSE currently being conducted in 435 factories of the Shanghai Textile Industry Bureau. The purpose of the study is to determine whether the regular practice of BSE will reduce mortality from breast cancer. Over 267,000 current and retired female workers between the ages of 30 and 64 in 1989 were randomized by factory to an intervention or control group. Women in the intervention group received initial BSE instruction in 1989-91, reinforcement sessions in 1991-92 and 1993-95, and multiple interim reminders to practice BSE, and had their BSE supervised by a medical worker twice a year. All women are being actively followed for vital status and residence in Shanghai, and multiple active and passive methods are utilized to identify all incident and fatal breast cancers. High levels of compliance and competency in practicing BSE for the first five years of the trial have been documented, as has the capacity to track a high proportion of women in the study and identify virtually all breast cancer deaths. As anticipated from results of mammography trials, breast cancer mortality rates through year 4 of follow-up (1994) were similar in the two study arms, and follow-up for 10 years (through the year 2000), as originally anticipated, will be necessary, and is proposed in this renewal application. No further intervention activities are proposed. After 10 years of follow-up, over 2.6 million woman-years will have accrued, and this trial will have 80% power to detect a reduction in breast cancer mortality of 30%.